Vaccine based on simulating human blood vessel endothelial cell growth factor VEGF epitope and preparation method thereof

A technology that mimics epitopes and vascular endothelium, applied in the field of medicine and biology, can solve the problems of immune incompetence, inability to be activated, and inability to activate functions, so as to reduce the side effects of monoclonal antibodies, reduce the burden on patients, inhibit the proliferation of vascular endothelial cells and The effect of migration

Inactive Publication Date: 2009-05-13
FOURTH MILITARY MEDICAL UNIVERSITY
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In fact, there are three mechanisms that lead to immune tolerance: cell line knockout, that is, specific lymphocytes are completely eliminated from the lymphocyte population; immune anergy, that is, specific lymphoc

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine based on simulating human blood vessel endothelial cell growth factor VEGF epitope and preparation method thereof
  • Vaccine based on simulating human blood vessel endothelial cell growth factor VEGF epitope and preparation method thereof
  • Vaccine based on simulating human blood vessel endothelial cell growth factor VEGF epitope and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0068] The present invention will be described in further detail below in conjunction with the accompanying drawings and embodiments.

[0069] The VEGF therapeutic autovaccine prepared according to the technical scheme of the present invention first applies the method of affinity screening and utilizes Avastin as a ligand to randomly present 12 peptide libraries in phage ( , New England) to obtain high affinity 12 peptide mimotope Asp-His-Thr-Leu-Tyr-Thr-Pro-Tyr-His-Thr-His-Pro (aspartic acid-histidine-threonine acid-leucine-tyrosine-threonine-proline-tyrosine-histidine-threonine-histidine-proline), after chemically synthesizing the epitope, glutaraldehyde It is chemically coupled with KLH to obtain a vaccine capable of breaking autoimmune tolerance and producing autoantibodies.

[0070] To realize the screening of the peptide library of the present invention, the construction of the vaccine, and the immunization of animals, the work of antibody detection is completed accord...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a vaccine based on an epitope simulating human vascular endothelial growth factor VEGF, as well as a preparation method thereof. A VEGF mimic epitope which is specifically affinitive with human-mouse chimeric monoclonal antibody Avastin is screened out by use of a phage random presentation technique, and the amino acid sequence of the mimic epitope is Asp-His-Thr-Leu-Tyr-Thr-Pro-Tyr-His-Thr-His-Pro; the mimic epitope has no homology with the protein sequence of VEGF. A vaccine which can induce a polypeptide epitope aiming at VEGF molecular autoantibody in vivo is constructed on the basis of the mimic epitope. The invention provides a strategy for developing and designing the tumor therapeutic vaccine, which is targeted at the VEGF. The VEGF is one of molecules which has the strongest effect of promoting vascular growth, and is an ideal target for resisting angiogenesis and treating tumors. Therefore, the vaccine replaces or replenishes monoclonal antibody passive immunotherapy with an active immunity mode, so as to lay foundations for overcoming the defects of monoclonal antibody therapy.

Description

technical field [0001] The invention belongs to the field of medical biotechnology, and specifically relates to a mimetic epitope based on simulating human vascular endothelial cell growth factor VEGF and a polypeptide epitope vaccine capable of inducing autoantibodies against VEGF molecules in vivo constructed by using the mimetic epitope and its Preparation. Background technique [0002] 1. Research on VEGF molecules and their monoclonal antibodies [0003] 1.1 VEGF molecules [0004] The relative molecular weight of VEGF is 34-42KD, which is composed of homodimers with a molecular weight of 17-22KD linked by disulfide bonds. The gene structure of human VEGF is located at chromosome 6p21.3. The gene is 28kb in length, and the gene encoding VEGF is about 14,000 base pairs long, consisting of 8 exons and 7 introns alternately. There are five isoforms of VEGF due to the different splicing modes of VEGF mRNA. According to the size of amino acids, they are named VEGF206 (in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K7/08C40B30/04G01N33/577A61K39/00A61P35/00
Inventor 张英起冉永刚韩苇
Owner FOURTH MILITARY MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products